Veliparib (ABT-888)

For research use only. Not for use in humans.

目录号:S1004 别名: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Veliparib 可增加自噬和凋亡。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1277.12 现货
RMB 973.01 现货
RMB 1859.13 现货
RMB 3010.72 现货
RMB 5053.23 现货
RMB 8108.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Veliparib (ABT-888)发表文献133篇:

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Veliparib (ABT-888)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Veliparib 可增加自噬和凋亡。Phase 3。
特性 ABT-888增强常见癌症疗法的效果,比如放射疗法和烷基化剂。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
体外研究

ABT-888有效抑制PARP,作用于PARP-1和PARP-2时Ki值分别为5.2和2.9 nM。ABT-888降低肺癌H460细胞中克隆基因的存活率,且抑制DNA修复。[1]ABT-888抑制C41细胞,EC50为2 nM。[2] ABT-888和放射物联用减少肿瘤血管的形成。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 MlvvT4lv[XOnIFHzd4F6 MWCzNEBucW5? Mni3TY5pcWKrdHnvckBw\iCSQWLQNUB4cXSqIFXDOVAhd2ZiMD6wNFIh|ryP NU\Fc2E4OTl6OEi3OlA>
Jurkat NYL6XYlsU2mwYYPlJGF{e2G7 NELWbos6PiCq MXfEUXNQ NUHPNG1MUW6qaXLpeIlwdiCxZjDQRXJROSCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImge4l1cCCHQ{WwJI9nKDNizszN NHXzRYwzOzh3MEG5PS=>
Capan1 M2[2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[wO|IhcA>? MWXEUXNQ MkfpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? MonSNlQ{QTh|OEO=
DT40 MUfDfZRwfG:6aXOgRZN{[Xl? NHjEcYM4OiCq NVfV[5NZTE2VTx?= MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBkcGmla3XuJGJTS0F{LXTl[olkcWWwdDDEWFQxKGOnbHzz MVeyOFkzOjV6Nx?=
ML-1 MoTIRZBweHSxdHnjJGF{e2G7 M4j4RlIvPSEQvF2= MXmyOEBp MVTEUXNQ MmHGV5lv\XKpaYP0bYNidGy7IHXubIFv[2W|IGTSRWlNNWmwZIXj[YQh[XCxcITvd4l{KGmwIF3MMVEh[2WubIO= NUPrRXVrOjR6OUWxN|U>
HCT-116 MmXzT4lv[XOnIFHzd4F6 M{Txc|AvPSEQvF2= MXGyOEBp MoDMVGFTWCCjY4Tpeol1gSCmZXPy[YF{\XN? M3TKcVI{ODV2MkGz
UM-SCC1 MkLhR5l1d3SxeHnjJGF{e2G7 NHzMWpgyOCEQvF2= NHj1d4MzPCCq NUnGTXdmWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> MUGyNVkyOjZ{MB?=
FaDu Mnm2R5l1d3SxeHnjJGF{e2G7 Mne5NVAh|ryP Mkn3NlQhcA>? Moj6VoVlfWOnczD0bIUh[2WubDD2bYFjcWyrdIm= MXuyNVkyOjZ{MB?=
PC-3 NHzxOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXiW28yOCEQvF2= NX;iPWQ5UW6mdXPld{BiKHOrZ37p[olk[W62IHnubIljcXSrb36gbY4h[2:ub375JIZwem2jdHnvcuKh M4DldFIyPTdzOUGy
EoL-1-cell MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLZR49KSzVyPUGuNFc6QCEQvF2= M1vPcHNCVkeHUh?=
NCI-SNU-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNwMUK4OFEh|ryP NG\Pb4NUSU6JRWK=
BV-173 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXYTWM2OD13LkS1OFA6KM7:TR?= NGTkR5ZUSU6JRWK=
HCC1806 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvidWVKSzVyPUWuO|UyPzNizszN NFW0UoZUSU6JRWK=
COLO-680 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTZwMkG0NFYh|ryP M2fkVXNCVkeHUh?=
HCC2218 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\HcG1KSzVyPUeuO|k4ODRizszN M2\nW3NCVkeHUh?=
SK-MEL-24 NGrX[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzQTWM2OD15LkixPVI1KM7:TR?= NEK4PY9USU6JRWK=
NCI-H720 NXrTZ5BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojVTWM2OD16LkSzOlA{KM7:TR?= Ml3KV2FPT0WU
KASUMI-1 M3rHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfBVIVtUUN3ME24Mlg6OjZ4IN88US=> MnL0V2FPT0WU
HAL-01 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn6OZlbUUN3ME25Mlg5PjJizszN NUD1Tph1W0GQR1XS
CAL-33 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W3SmlEPTB;MUCuOFM1KM7:TR?= NFrET2NUSU6JRWK=
SK-MEL-1 M1nBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjJT5pKSzVyPUGyMlQ3PjNizszN NV2xcGxPW0GQR1XS
Ramos-2G6-4C10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\4PWlEPTB;MUKuOFc2OiEQvF2= NF\rRlRUSU6JRWK=
KY821 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPkTWM2OD1zMj60PFUh|ryP MmC0V2FPT0WU
HEC-1 NFLiR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIWwfoZKSzVyPUGyMlkyQTZizszN MoLXV2FPT0WU
SK-NEP-1 M2nKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXkXIo6UUN3ME2xN{4yPjZizszN MmfwV2FPT0WU
MN-60 NEjHc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXm[mxJUUN3ME2xN{42Ozh7IN88US=> M2jDNnNCVkeHUh?=
DU-145 NWXleXlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXBVJVKSzVyPUGzMlkxPTNizszN MoDvV2FPT0WU
EW-3 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF2LkW1OlUh|ryP MXPTRW5ITVJ?
OS-RC-2 M3TvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vNb2lEPTB;MUWuPVU5QSEQvF2= NUXmWIkxW0GQR1XS
RPMI-8226 M{nVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HIRWlEPTB;MU[uNlA1OiEQvF2= NGnwfWtUSU6JRWK=
ChaGo-K-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO0WnZKSzVyPUG2MlU{OjVizszN Mlm5V2FPT0WU
DEL NG\Jb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLuTWM2OD1zNj62O|E4KM7:TR?= NUi0RoJ6W0GQR1XS
GP5d MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF5LkC1N{DPxE1? MoD6V2FPT0WU
COLO-668 NF7MeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPUTWM2OD1zNz62Nlk1KM7:TR?= M{D5fHNCVkeHUh?=
H9 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Oy[2lEPTB;MUiuNlg{OyEQvF2= M3y5eHNCVkeHUh?=
NKM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjrTXNKSzVyPUG4MlUyOTlizszN M4jyT3NCVkeHUh?=
KYSE-150 M{\Lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzkUnN4UUN3ME2xPE46QTh4IN88US=> M3jEdnNCVkeHUh?=
Daoy MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPtTWM2OD1zOT61OlQ6KM7:TR?= M2\OPHNCVkeHUh?=
ECC10 Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJyLke0OVUh|ryP NILJPVVUSU6JRWK=
A388 NYS1fIJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPkfJhWUUN3ME2yNU46ODlzIN88US=> NHTYVmVUSU6JRWK=
MHH-NB-11 M4PkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHpTWM2OD1{Mz6xN|Y{KM7:TR?= M4TTbHNCVkeHUh?=
HCC1937 M{H2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlKyTWM2OD1{ND63OFYh|ryP NWe1SnJbW0GQR1XS
TGBC11TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\QO3EzUUN3ME2yOU43QDZ|IN88US=> NXixVINYW0GQR1XS
CTV-1 NUWzTlJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rCcWlEPTB;MkWuPFk3QSEQvF2= NXHJTG5VW0GQR1XS
NCI-H2029 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzwVJdKSzVyPUK2MlQzOzhizszN NIPXToFUSU6JRWK=
HLE M{i3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\4XGlEPTB;MkeuNFU1KM7:TR?= NVTBfmJnW0GQR1XS
NCI-H1693 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV60VZlkUUN3ME2yO{4zQDl6IN88US=> MoG4V2FPT0WU
HCC70 NUTPR41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfabXNKSzVyPUK3MlczPDZizszN NI[wN3dUSU6JRWK=
BEN NHLSdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Sye2lEPTB;MkeuPVU3PiEQvF2= NETIOJVUSU6JRWK=
LB771 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPPV4R5UUN3ME2yPE45Ozd|IN88US=> MXTTRW5ITVJ?
697 M3e3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\xcmlEPTB;MkmuNFI{PSEQvF2= MlO0V2FPT0WU
LU-139 NI\xNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjYe4N7UUN3ME2yPU4{PzR6IN88US=> NUD2VIxwW0GQR1XS
EW-13 NFrveWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr2SZpKSzVyPUK5MlM5OTRizszN MkSxV2FPT0WU
MOLT-13 M37SZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ7LkO4NVQh|ryP NVvTUlBMW0GQR1XS
L-363 M3O1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ7LkS3PVgh|ryP NVLsSnJCW0GQR1XS
EM-2 NYnJRoUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTRZXRNUUN3ME2yPU41QTBzIN88US=> NWjVbG5GW0GQR1XS
RS4-11 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT6V5BNUUN3ME2zNE41OjRzIN88US=> NVy4O|htW0GQR1XS
A2780 M{frWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzBTWM2OD1|MD63OFU4KM7:TR?= MkDqV2FPT0WU
KU812 NI\rcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr5RmNKSzVyPUOyMlM3PDJizszN Mn:1V2FPT0WU
COLO-684 NVjUfJhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfHcIdlUUN3ME2zN{4{PTl7IN88US=> M2XaTnNCVkeHUh?=
MFE-280 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fGdmlEPTB;M{OuN|g5QSEQvF2= MUTTRW5ITVJ?
KG-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuwSZhKSzVyPUOzMlYxODFizszN NVPtcVJNW0GQR1XS
JVM-3 NVnETG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f2SmlEPTB;M{WuOVg3QCEQvF2= MWnTRW5ITVJ?
MV-4-11 NHfzWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkniTWM2OD1|NT64OFk6KM7:TR?= NELROIRUSU6JRWK=
LAMA-84 NUn1Ro8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv0U4w1UUN3ME2zOk44OzR3IN88US=> MUfTRW5ITVJ?
MOLT-16 NIrJU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7BTWM2OD1|Nj65OVIh|ryP NWTZeolKW0GQR1XS
H4 M{TQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP3RllKSzVyPUO3MlU3PyEQvF2= MXfTRW5ITVJ?
T47D MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6dGlEPTB;M{euO|AyQCEQvF2= M4XSTXNCVkeHUh?=
CAL-54 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\Jc2F3UUN3ME2zO{46PjZizszN M3zTdnNCVkeHUh?=
SW982 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjpPVdMUUN3ME2zPE4xQTl6IN88US=> MkjkV2FPT0WU
IGROV-1 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3tcJlGUUN3ME2zPU4{OzB2IN88US=> M3XxWHNCVkeHUh?=
NB14 NITsO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13SPWlEPTB;NECuO|A{OSEQvF2= MYHTRW5ITVJ?
HCC1187 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrFTWM2OD12MT6yO|cyKM7:TR?= NH3ISI5USU6JRWK=
SBC-1 NF64b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnhTWM2OD12MT6zNFY{KM7:TR?= NGLjZ4JUSU6JRWK=
KARPAS-45 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRzLkS4NVgh|ryP NFnrRYFUSU6JRWK=
MOLT-4 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrCTWM2OD12Mj6yOVM5KM7:TR?= MoH3V2FPT0WU
JVM-2 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr6TWM2OD12Mj65NlA4KM7:TR?= NIPpeYxUSU6JRWK=
A4-Fuk MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nJcmlEPTB;NEOuOVY6OSEQvF2= NIKxdVhUSU6JRWK=
MDA-MB-361 NF:yWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrOPVBmUUN3ME20N{45PDF2IN88US=> MVjTRW5ITVJ?
BALL-1 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn5[VN6UUN3ME20N{46PTN{IN88US=> MXPTRW5ITVJ?
T98G M2jnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTR2Lki1NVch|ryP M1PHfXNCVkeHUh?=
Mo-T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTR3Lk[zPFkh|ryP MlfDV2FPT0WU
MHH-PREB-1 M2DlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrsb3NKSzVyPUS1Mlc2QDVizszN M3LUNHNCVkeHUh?=
ALL-PO M2SyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2npSWlEPTB;NEeuN|c6OSEQvF2= NF;lSGtUSU6JRWK=
NCI-H510A Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHuO3dTUUN3ME20O{46ODN2IN88US=> M13ndnNCVkeHUh?=
ML-2 NF2yTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPFRW9lUUN3ME20PU44QDV4IN88US=> MVTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
体内研究 ABT-888推迟NCI-H460 移植瘤模型的肿瘤生长。ABT-888在B16F10 和9L 移植瘤模型中抑制PARP,从而增强temozolomide的抗癌活性。[1]ABT-888和其他细胞毒素药剂联用作用于MX-1移植瘤模型时显示出强抗癌效力。[2]在A375和 Colo829移植瘤模型中按肿瘤大小,每千克分别加3和12.5 mg ABT-888,可以看到肿瘤内95%以上PAR被抑制。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外PARP实验:

在含有50 mM Tris (pH 为8.0), 1 mM DTT,和 4 mM MgCl2的缓冲溶液中进行酶活性测定。PARP反应包含1.5 μM [3H]-NAD+ (1.6 μCi/mmol), 200 nM 生物素组蛋白 H1, 200 nM slDNA,及1 nM PARP-1或4 nM PARP-2酶。在加有100 μL 反应液的 96孔板上进行SPA检测。在50 μL含有PARP和DNA的2×酶液混合物中加入50 μL 2×NAD+基底混合物,反应开始。加入150 μL 1.5 mM 苯甲酰胺反应停止。170uL反应终止液转移到链霉亲和素包被的闪熔镀层上,温育1小时,用微型板块闪烁计数器计数。
细胞实验:[2]
- 合并
  • Cell lines: C41细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 0.5小时
  • Method: 在96孔板上用ABT-888处理C41细胞0.5小时。用1 mM H2O2破坏DNA10分钟,PARP被激活。用冰冻的PBS冲洗细胞,然后用预冷的甲醇/丙酮(按7:3比例混合)在−20oC下固定10 分钟。风干后,用PBS再溶解,然后用溶有5%脱脂奶粉的PBS- Tween封闭液(0.05%)在室温下阻断0.5小时。细胞和PAR抗体按1:50比例在封闭液中室温下温育1小时,然后用PBS-Tween-20冲洗5分钟,然后加入荧光素-5(6)-异硫氰酸酯 (FITC)-联用的二抗和1μg/mL DAPI封闭液中室温下温育1小时。PBS-Tween-20冲洗5分钟后,用荧光微型版计数器分析数据。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带NCI-H460, H460, B16F10和9L移植瘤的C57BL/6鼠
  • Dosages: 25或3.125 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
0.5% methylcellulose+0.2% Tween 80
5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 244.29
化学式

C13H16N4O

CAS号 912444-00-9
储存条件 粉状
溶于溶剂
别名 NSC 737664

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Veliparib (ABT-888) | Veliparib (ABT-888)供应商 | 采购Veliparib (ABT-888) | Veliparib (ABT-888)价格 | Veliparib (ABT-888)生产 | 订购Veliparib (ABT-888) | Veliparib (ABT-888)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID